Trial Profile
A 5-year study to compare the durability of glycemic control of a combination regimen with vildagliptin & metformin versus standard-of-care monotherapy with metformin, initiated in treatment-naive patients with type 2 diabetes mellitus
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Jan 2023
Price :
$35
*
At a glance
- Drugs Metformin (Primary) ; Vildagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms VERIFY
- Sponsors Novartis; Novartis Healthcare; Novartis Pharmaceuticals
- 07 Jun 2022 Results presented at the 82nd Annual Scientific Sessions of the American Diabetes Association
- 29 Jun 2021 Results (N=405) of a sub analysis of prandial beta-cell function in patients undergoing a standard meal test presented at the 81st Annual Scientific Sessions of the American Diabetes Association
- 25 Sep 2020 Results presented at the 56th Annual Meeting of the European Association for the Study of Diabetes